Vu L. Truong - 04 May 2023 Form 4 Insider Report for Aridis Pharmaceuticals, Inc.

Role
CEO and Director, Director
Signature
/s/ Vu Truong
Issuer symbol
N/A
Transactions as of
04 May 2023
Net transactions value
$0
Form type
4
Filing time
15 Jun 2023, 17:13:37 UTC
Previous filing
07 Dec 2022
Next filing
19 Sep 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ARDS Common Stock Options Exercise +15,000 +2% 752,353 05 Jun 2023 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ARDS Stock Options Award $0 +100,000 +15% $0.000000 787,750 04 May 2023 Common Stock 100,000 $0.1600 Direct F1
transaction ARDS Restricted Stock Units Options Exercise -15,000 -50% 15,000 05 Jun 2023 Common Stock 15,000 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 50% of the options vest on the three month anniversary of the date of grant and the remainder vest on the six month anniversary of the date of grant.
F2 Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
F3 15,000 shares of Common Stock vested on June 5, 2023 and 15,000 will vest on 12/5/2023. In the event that the Reporting Person's employment is terminated without cause by the Issuer, the RSUs will immediately vest.